

TENET HEALTHCARE CORP  
Form 8-K  
January 22, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 22, 2013**

**TENET HEALTHCARE CORPORATION**

(Exact name of registrant as specified in its charter)

**Nevada**  
(State or other jurisdiction of  
incorporation)

**1-7293**  
(Commission File Number)

**95-2557091**  
(IRS Employer Identification No.)

**1445 Ross Avenue, Suite 1400, Dallas, Texas**  
(Address of principal executive offices)

**75202**  
(Zip Code)

Registrant's telephone number, including area code: **(469) 893-2200**

**Not Applicable**

Former name or former address, if changed since last report.)

## Edgar Filing: TENET HEALTHCARE CORP - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 7.01**

**Regulation FD Disclosure**

On January 22, 2013, Tenet Healthcare Corporation (the Company) issued a press release announcing that it had commenced a tender offer to purchase for cash any and all of its outstanding 10% senior secured notes due 2018 and a solicitation of consent for proposed amendments to the related indenture, on the terms set forth in an offer to purchase and consent solicitation statement dated January 22, 2013, and related letter of transmittal, dated January 22, 2013. The Company refers investors participating in the tender offer and consent solicitation to the tender offer and consent solicitation documents for the complete terms of the tender offer and consent solicitation. A copy of the press release is attached to this report as Exhibit 99.1 and incorporated herein by reference.

**Item 8.01**

**Other Events**

On January 22, 2013, the Company issued a press release announcing that it had commenced a private offering of \$850 million in aggregate principal amount of senior secured notes due 2021. A copy of the press release is attached to this report as Exhibit 99.2 and incorporated herein by reference. On January 22, 2013, the Company issued a press release announcing the pricing of its offering of senior secured notes due 2021. A copy of the press release is attached to this report as Exhibit 99.3 and incorporated herein by reference.

**Item 9.01**

**Financial Statements and Exhibits**

(d) The following exhibits are filed as a part of this Report.

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued on January 22, 2013
99.2	Press release issued on January 22, 2013
99.3	Press release issued on January 22, 2013

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TENET HEALTHCARE CORPORATION

Date: January 22, 2013

By:	/s/ Paul Castanon	
Name:		Paul Castanon
Title:		Vice President, Deputy General Counsel and Corporate Secretary

**EXHIBIT INDEX**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release issued on January 22, 2013
99.2	Press release issued on January 22, 2013
99.3	Press release issued on January 22, 2013